Trial NCT01754376

View at ClinicalTrials.gov 
Org. Study IDs: 12-343

Last trial update was posted on 2017-04-12

MeSH Interventions

Aldesleukin Interleukin-2 Vemurafenib

MeSH Conditions

Melanoma

Other Conditions


Stopping Reasons

changes in available treatments for melanoma

Limitations And Caveats

The protocol terminated early due to a dramatic change in the treatment landscape for treating BRAF mutant melanoma (e.g. one BRAF/MEK inhibitor combination and two anti-PD1 antibodies were approved by the FDA while this study was open).

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID